DeciBio Insights

Emmes Data Insights: Hospital Labs’ Readiness for the Coronavirus Testing Onslaught

Diagnostics Market, Emmes Data Insights

 

SARS-CoV-2 media attention has largely focused on diagnostic reference labs as they have scaled up testing capacity. However, hospital labs, which drive the vast majority of seasonal respiratory virus testing in the U.S., have received much less attention. Hospital labs offer important advantages over reference labs in the current testing environment, where long sample-to-answer time leaves patients in limbo and uses up scarce PPE. The simplified logistics of testing in local hospital laboratories also reduces the backlog at centralized hubs. Here we make sense of the fragmented landscape of coronavirus testing options currently available and examine which tests will likely most easily enter hospital laboratories, based on insights from DeciBio’s Emmes Infectious Disease database.

Worldwide, there are ~100 commercially available diagnostics tests for SARS-CoV-2 coronavirus. Of these, 42 have sought U.S. emergency use authorization (EUA), 34 of which have been approved to date. While ARUP, LabCorp, Quest, and other leading private labs have developed their own tests, the vast U.S. hospital lab network is relying first on tests that are compatible with their existing installed base and in-house expertise.

The DeciBio Emmes Infectious Disease database provides insights into hospitals’ testing capabilities. The database curates testing behaviors and trends from 1,000+ U.S. hospital labs annually to provide high-quality, granular insights on infectious disease testing practices nationwide. Historically, hospital labs have been responsible for ~45% of total U.S. respiratory virus testing volume (including influenza, RSV, and respiratory viral panels). Of the 1.3 million hospital-based respiratory virus tests captured in 2019, ~80% are processed in hospitals with over 200 beds.

The 5 most common platforms these hospitals use for respiratory viruses cover ~2/3 of total test volume; here are leading platforms and their corresponding tests, if available:

 

Leading Molecular Diagnostic Platforms in U.S. Hospitals

Platform rank by U.S. testing volume, all analytesPlatform rank by U.S. testing volume, respiratory viruses*Platform**SARS-CoV-2 TestEUA Status
11Cepheid GeneXpert and GeneXpert XpressXpert Xpress SARS-CoV-2 testEUA 3/20/2020
 2N/AHologic PantherNone; Hologic test only compatible with Panther FusionEUA 3/16/2020***
3N/ARoche Cobas 4800None; Roche test only compatible with Cobas 6800/8800EUA 3/12/2020***
43Cepheid InfinityXpert Xpress SARS-CoV-2 testEUA 3/20/2020
52BioMerieux BioFire Film & TorchBioFire COVID-19 test (compatible with both platforms)EUA 3/23/2020
616BD MaxBioGX SARS-CoV-2 Reagents for BD MAXEUA 4/2/2020
134Abbott ID NOW (formerly Alere i)ID NOW COVID-19EUA 3/27/2020
106Luminex VerigeneNone; Luminex NxTAGCoV Assay compatible with MAGPIX system, while ARIES Assay only compatible with Aries systemEUAs 3/27/2020 and 4/3/2020***

 

As coronavirus testing continues to scale, we are seeing increased demand for both SARS-CoV-2 and traditional respiratory virus tests for differential diagnosis. While coronavirus tests with EUA are now available for most platforms that hospitals use, Hologic’s and Roche’s offerings face the challenge of a limited compatible installed base despite the high penetration of these companies within the hospital testing market. While many institutions will likely require new platforms in order to bring coronavirus testing in-house, influenza testing on installed coronavirus-incompatible machines remains highly valuable. As the urgent race to expand testing capacity continues, hospital labs have a critical role to play in distributing the testing burden and decreasing turnaround time, and many of their existing machines are proving valuable in the fight.

 

These insights were generated from DeciBio’s Emmes infectious disease market intelligence database. Stay tuned for future insights as we gather data about coronavirus testing around the U.S., and reach out to DeciBio to schedule a demo and see how Emmes can answer your questions.

 

* Includes panels that may contain respiratory viruses, bacteria, and other pathogens

** Not a comprehensive list; platforms not shown due to low existing testing volumes in hospital labs include the Thermo Fisher AB 7500, Abbott m2000, and numerous others

*** EUA granted for a test by this manufacturer, but the approved test is not compatible with the hospital-used platform listed here


Julia daniel

 

 

Julia is a Senior Analyst at DeciBio with a focus on health technology, clinical diagnostics, and the impact of machine learning on precision medicine. Julia’s work at DeciBio includes market intelligence, voice-of-customer research, and data tools development. Connect with her on LinkedIn or reach out at [email protected].

 

 

Disclaimer: Companies listed above may be DeciBio clients and/or customers

Interested in learning more about the Emmes Infectious Disease Database? Reach out to DeciBio to schedule a demo and see how Emmes can answer your questions.